Micron, Moody’s, Digital Realty and a Health Care Stock on CNBC’s ‘Final Trades’
CNBC traders picked Micron, Digital Realty, Natera and Moody’s; Natera raised FY2026 sales guidance after strong results, while Moody’s missed estimates.
Stocks · News reference
Natera announced it will present new data on its Signatera molecular residual disease test at the Society for Immunotherapy of Cancer (SITC) Annual Meeting.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
CNBC traders picked Micron, Digital Realty, Natera and Moody’s; Natera raised FY2026 sales guidance after strong results, while Moody’s missed estimates.
Natera, Inc. has entered into a clinical collaboration agreement with Incyte to evaluate the investigational bispecific immunotherapy INCA33890 in a new Phase II study for colorectal cancer patients.
Analyst Max Masucci of Roth MKM maintained a 'Buy' rating on Natera, Inc. while adjusting the price target to $405.
Baird analyst Catherine Ramsey Schulte maintained a Buy rating on Natera, Inc. and increased the price target to $403.